Compositions and methods for treating autoimmune and inflammatory disorders
View Patent ↗Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
1. A vector comprising a nucleic acid molecule encoding a herpesvirus entry mediator (HVEM) polypeptide variant, wherein the variant specifically binds B and T lymphocyte attenuator (BTLA) and does not bind CD160, wherein the variant is truncated as compared to a wild-type HVEM protein, the variant comprising cysteine rich domain (CRD) 1 and CRD2 and lacking CRD4 of the wild-type HVEM protein; and wherein the variant comprises an amino acid substitution at residue position 109 from the starting methionine, the substitution being R109W.
2. The vector of claim 1 , wherein the variant has at least one additional amino acid substitution.
3. The HVEM polypeptide variant of claim 1 , wherein the variant comprises CDR1, CDR2 and a portion of CDR3.
4. The HVEM polypeptide variant of claim 3 , wherein the variant comprises an additional amino acid substitution at residue position 59, 60, 61, 72, or 82, or any combination thereof.
5. The HVEM polypeptide variant of claim 4 , wherein the variant comprises one or more of P59S, G60D, Y61C, G72P, and T82P.
6. The HVEM polypeptide variant of claim 4 , wherein the variant comprises an amino acid substation at residue position 59.
7. The vector of claim 1 , wherein the variant consists of a R109W substitution.
8. The HVEM polypeptide variant of claim 1 , wherein the variant comprises CDR1 or a portion thereof.
9. The HVEM polypeptide variant of claim 8 , wherein the variant comprises an amino acid substitution at residue position 59, 60, 61, 72 or any combination thereof.
10. The HVEM polypeptide variant of claim 9 , wherein the variant comprises one or more of P59S, G60D, Y61C and G72P.
11. The HVEM polypeptide variant of claim 10 , wherein the variant comprises an amino acid substation at residue position 59.
12. The vector of claim 1 , wherein the variant further comprises a dimerizing domain.
13. The vector of claim 12 , wherein the dimerizing domain is an antibody Fc domain.
14. The vector of claim 13 , wherein the Fc domain is an immunoglobulin (Ig) Fc domain.
15. The vector of claim 14 , wherein the Ig Fc domain is an IgA, IgD, IgE, IgG, or IgM Fc domain.
16. The vector of claim 15 , wherein the Ig Fc domain is an IgG1 Fc domain.
17. The HVEM polypeptide variant of claim 2 , wherein the variant comprises amino acid residues from about 39 to 120, about 39 to 141, or about 39 to 163 of SEQ ID NO: 79.
18. A pharmaceutical composition comprising a nucleic acid molecule encoding the vector of claim 1 , and a pharmaceutically acceptable carrier.
19. An isolated nucleic acid molecule encoding the vector of claim 1 .
20. An expression cassette comprising the nucleic acid molecule of claim 19 .
21. A vector comprising the expression cassette of claim 20 .
22. An isolated host cell transformed or transfected with the nucleic acid molecule of claim 19 or the vector of claim 21 .
23. A method for treating an inflammatory disease in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising the HVEM polypeptide variant of claim 1 , wherein the administering results in treatment of the inflammatory disease.
24. The method of claim 23 , wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, lupus, autoimmune diseases, Crohn's disease, ulcerative colitis, inflammatory bowel diseases, asthma, dermatitis, diverticulitis, pelvic inflammatory disease, atherosclerosis, allergies, myopathies, and leukocyte defects.
25. A method of inhibiting a proinflammatory response in a subject comprising administering to the subject an effective amount of a pharmaceutical composition comprising the HVEM polypeptide variant of claim 1 , wherein the administering results in inhibition of the proinflammatory response.
26. The method of claim 25 , wherein the agent inhibits activation of natural killer (NK) cells.
27. The method of claim 25 , wherein the agent is a negative regulator of IL-2 signaling.
28. The method of claim 25 , wherein the agent is a polypeptide.